the Effect of Probiotics on Aging Population (TEOPOGP)
Primary Purpose
Debility
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Bifidobacterium longum
A placebo made of starch
Sponsored by
About this trial
This is an interventional treatment trial for Debility focused on measuring intestinal flora
Eligibility Criteria
Inclusion Criteria:
- Over 65 years old
- Frail scale score above 3 points
Exclusion Criteria:
- Severe impairment of liver and kidney function
- The tumor is advanced and life expectancy is less than 2 years
- Severe cognitive impairment and inability to cooperate
- Unable to give informed consent
- Have participated in other study before
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
the placebo group
Bifidobacterium longum group 1
Bifidobacterium longum group 2
Bifidobacterium longum group 3
Arm Description
A placebo made of starch
Bifidobacterium longum 274
Bifidobacterium longum 4-1
Bifidobacterium longum gs
Outcomes
Primary Outcome Measures
Points of probiotics intervention in aging population
The score of Frail scale 0 points is defined as normal.And 1 to 3 points is defined as the early age of debility.Three points or more is defined as debility.The score is lower than before, meaning probiotic intervention can alleviate debility.
Secondary Outcome Measures
Full Information
NCT ID
NCT04911556
First Posted
May 12, 2021
Last Updated
June 2, 2021
Sponsor
Wuxi People's Hospital
Collaborators
Jiangnan University
1. Study Identification
Unique Protocol Identification Number
NCT04911556
Brief Title
the Effect of Probiotics on Aging Population
Acronym
TEOPOGP
Official Title
Study for the Effect of Probiotics on Aging Population
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2021 (Anticipated)
Primary Completion Date
June 30, 2022 (Anticipated)
Study Completion Date
December 31, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wuxi People's Hospital
Collaborators
Jiangnan University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study intends to recruit aging population (over 65 years old). The investigators use 16 SrDNA sequencing technology, genome sequencing technology, metabonomics, random forest forecast model, analysing and selecting specific age-related intestinal flora. The investigators select probiotics slowing down senility. Then the investigators use the probiotics to intervene in the aging population. Finally the investigators observe whether the probiotics can delay aging.
Detailed Description
This project plans to recruit the aging population (aged over 65 years old) and comprehensively analyze the public database and self-sequencing clinical big data by using 16 srDNA sequencing technology, metagenomic sequencing technology, metabonomics methods and Random Forest (R) prediction model to judge the key bacterial communities and related functional pathways related to aging.Based on the analysis results, the probiotics with the potential to alleviate aging were selected for intervention evaluation of aging population. This topic aims to explore the change process of intestinal flora structure and composition related to aging process.Identify the key intestinal bacteria genera/species/strains associated with aging, and target the pathway and metabolic characteristic spectrum of the key bacterial communities associated with aging;And select and breed specific intestinal bacterial strains related to aging.The aim is to reduce the age-related metabolic abnormalities and chronic inflammation, reduce medical treatment, rationally allocate medical resources, reduce medical costs and improve the quality of life.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Debility
Keywords
intestinal flora
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
One group served as a control group, while the other three groups are treated with different strains of bifidobacterium longum
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participant ,care provider,investigator and outcomes Assessor are all blind.
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
the placebo group
Arm Type
Placebo Comparator
Arm Description
A placebo made of starch
Arm Title
Bifidobacterium longum group 1
Arm Type
Experimental
Arm Description
Bifidobacterium longum 274
Arm Title
Bifidobacterium longum group 2
Arm Type
Experimental
Arm Description
Bifidobacterium longum 4-1
Arm Title
Bifidobacterium longum group 3
Arm Type
Experimental
Arm Description
Bifidobacterium longum gs
Intervention Type
Dietary Supplement
Intervention Name(s)
Bifidobacterium longum
Intervention Description
types of intestinal flora
Intervention Type
Dietary Supplement
Intervention Name(s)
A placebo made of starch
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Points of probiotics intervention in aging population
Description
The score of Frail scale 0 points is defined as normal.And 1 to 3 points is defined as the early age of debility.Three points or more is defined as debility.The score is lower than before, meaning probiotic intervention can alleviate debility.
Time Frame
one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Over 65 years old
Frail scale score above 3 points
Exclusion Criteria:
Severe impairment of liver and kidney function
The tumor is advanced and life expectancy is less than 2 years
Severe cognitive impairment and inability to cooperate
Unable to give informed consent
Have participated in other study before
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kan Hong, doctor
Phone
13358119885
Email
2898456291@qq.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kan Hong, doctor
Organizational Affiliation
Wuxi People's hospitial
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
the Effect of Probiotics on Aging Population
We'll reach out to this number within 24 hrs